Harnessing the Immune System to fight Cancer and Infectious diseases
Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Takis partner of EIT Health featured in the film: Armed with innovation: The fight to beat the pandemic
February 3, 2021 - Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency (AIFA) of COVID-eVax
Trials to begin at the end of February
Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency (AIFA) of COVID-eVax, the vaccine against COVID-19 designed by Takis and developed in collaboration with Rottapharm Biotech.
March 1, 2021 - The first healthy volunteers received the initial dose of the DNA vaccine against COVID-19 (COVID-eVax) designed by Takis and developed in collaboration with Rottapharm Biotech in Italy: it is the first DNA vaccine to reach the clinical stage in Europe.
eit HEALTH - European Union
Progetto di ricerca e sviluppo “Messa a punto di metodi di produzione e purificazione di vettori di espressione per uso clinico: AAV, HSV-1, MVA e DNA - VECTOPUR”
Cofinanziamento dell’Unione Europea - FESR, PON Imprese e Competitività 2014-2020
CUP B88I17000100008
Progetto "DALLA GENOMICA ALLA TERAPIA DI TUMORI RARI - CUP B61C17000060007"
Cofinanziato dall’Unione Europea, dallo Stato Italiano e dalla Regione Campania, nell’ambito del POR Campania FESR 2014 - 2020
